StreetInsider.com News Articles

Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tue, 01 Sep 2026 16:05:00 -0400

REDWOOD CITY, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (the “Company” or “Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that on September 1, 2026 (the “Grant Date”), Pulmonx granted equity awards under its 2025 Inducement Plan (the “Inducement Plan”) to four individuals hired by Pulmonx in the third fiscal quarter of 2026. The awards were approved by the Compensation Committee of the Company’s Board of Directors and were granted as an inducement material to the new employees entering into employment with Pulmonx, in accordance with Nasdaq Listing

Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Tue, 01 Sep 2026 16:05:00 -0400

Pulmonx to Participate in Upcoming Investor Conferences

Thu, 27 Aug 2026 16:05:00 -0400

REDWOOD CITY, Calif., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced that management will participate in the following upcoming investor conferences:

Wells Fargo Healthcare Conference
Format: 1x1 meetings
Date: Wednesday, September 9
Location: Boston, MA

Lake Street Best Ideas Growth (BIG10) Conference
Format: 1x1 meetings
Date: Thursday, September 10
Location: New York, NY

About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD). Pulmonx’s Zephyr^® Endobronchial

Pulmonx to Participate in Upcoming Investor Conferences

Thu, 27 Aug 2026 16:05:00 -0400

Wells Fargo Healthcare Conference
Format: 1x1 meetings
Date: Wednesday, September 9
Location: Boston, MA

Lake Street Best Ideas Growth (BIG10) Conference
Format: 1x1 meetings
Date: Thursday, September 10
Location: New York, NY

Pulmonx to Participate in Upcoming Investor Conferences

Thu, 27 Aug 2026 16:05:00 -0400

Wells Fargo Healthcare Conference
Format: 1x1 meetings
Date: Wednesday, September 9
Location: Boston, MA

Lake Street Best Ideas Growth (BIG10) Conference
Format: 1x1 meetings
Date: Thursday, September 10
Location: New York, NY

Pulmonx to Participate in Upcoming Investor Conferences

Thu, 27 Aug 2026 16:05:00 -0400

Wells Fargo Healthcare Conference
Format: 1x1 meetings
Date: Wednesday, September 9
Location: Boston, MA

Lake Street Best Ideas Growth (BIG10) Conference
Format: 1x1 meetings
Date: Thursday, September 10
Location: New York, NY

Form SCHEDULE 13G/A Pulmonx Corp Filed by: MORGAN STANLEY

Thu, 13 Aug 2026 17:28:00 -0400

si-local-file:///var/storage/secattach/20260813/26922879.html

Form SCHEDULE 13G/A Pulmonx Corp Filed by: MORGAN STANLEY

Thu, 13 Aug 2026 17:28:00 -0400

si-local-file:///var/storage/secattach/20260813/26922879.html

Form 10-Q Pulmonx Corp For: Jun 30

Tue, 04 Aug 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260804/26867404.html

Form 10-Q Pulmonx Corp For: Jun 30

Tue, 04 Aug 2026 16:46:00 -0400

si-local-file:///var/storage/secattach/20260804/26867404.html

Pulmonx Corporation (LUNG) Tops Q2 EPS by 4c

Wed, 29 Jul 2026 16:48:24 -0400

Pulmonx Corporation (NASDAQ: LUNG) reported Q2 EPS of ($0.24), $0.04 better than the analyst estimate of ($0.28). Revenue for the quarter came in at $22.8 million versus the consensus estimate of $22.41 million.

For earnings history and earnings-related data on Pulmonx Corporation (LUNG) click here.

Form 8-K Pulmonx Corp For: Jul 29

Wed, 29 Jul 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260729/26835000.html

Form 8-K Pulmonx Corp For: Jul 29

Wed, 29 Jul 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260729/26835000.html

Pulmonx Reports Second Quarter 2026 Financial Results

Wed, 29 Jul 2026 16:05:00 -0400

REDWOOD CITY, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lung disease, today reported financial results for the second quarter of 2026 ended June 30, 2026.

Recent Highlights

Achieved worldwide revenue of $22.8 million in the second quarter of 2026, a 5% decrease over the same period last year and a decrease of 6% on a constant currency basis
Delivered $14.2 million in U.S. revenue in the second quarter of 2026, representing a 4% year-over-year decrease
Delivered $8.6 million

Pulmonx Reports Second Quarter 2026 Financial Results

Wed, 29 Jul 2026 16:05:00 -0400

Recent Highlights

Achieved worldwide revenue of $22.8 million in the second quarter of 2026, a 5% decrease over the same period last year and a decrease of 6% on a constant currency basis
Delivered $14.2 million in U.S. revenue in the second quarter of 2026, representing a 4% year-over-year decrease
Delivered $8.6 million

Pulmonx Reports Second Quarter 2026 Financial Results

Wed, 29 Jul 2026 16:05:00 -0400

Recent Highlights

Achieved worldwide revenue of $22.8 million in the second quarter of 2026, a 5% decrease over the same period last year and a decrease of 6% on a constant currency basis
Delivered $14.2 million in U.S. revenue in the second quarter of 2026, representing a 4% year-over-year decrease
Delivered $8.6 million

Pulmonx Reports Second Quarter 2026 Financial Results

Wed, 29 Jul 2026 16:05:00 -0400

Recent Highlights

Achieved worldwide revenue of $22.8 million in the second quarter of 2026, a 5% decrease over the same period last year and a decrease of 6% on a constant currency basis
Delivered $14.2 million in U.S. revenue in the second quarter of 2026, representing a 4% year-over-year decrease
Delivered $8.6 million

Form SCHEDULE 13G/A Pulmonx Corp Filed by: BlackRock, Inc.

Wed, 29 Jul 2026 15:23:00 -0400

si-local-file:///var/storage/secattach/20260729/26834399.html

Form SCHEDULE 13G/A Pulmonx Corp Filed by: BlackRock, Inc.

Wed, 29 Jul 2026 15:23:00 -0400

si-local-file:///var/storage/secattach/20260729/26834399.html

Pulmonx to Present at the Canaccord Genuity 46th Annual Growth Conference

Tue, 28 Jul 2026 16:05:00 -0400

REDWOOD CITY, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the Canaccord Genuity 46^th Annual Growth Conference in Boston on Tuesday, August 11, 2026, at 1:00 PM PT / 4:00 PM ET.

A live and archived webcast of the fireside chat will be available on “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.

About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global

Pulmonx to Present at the Canaccord Genuity 46th Annual Growth Conference

Tue, 28 Jul 2026 16:05:00 -0400

A live and archived webcast of the fireside chat will be available on “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.

About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global

Pulmonx to Present at the Canaccord Genuity 46th Annual Growth Conference

Tue, 28 Jul 2026 16:05:00 -0400

A live and archived webcast of the fireside chat will be available on “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.

About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global

Pulmonx to Present at the Canaccord Genuity 46th Annual Growth Conference

Tue, 28 Jul 2026 16:05:00 -0400

A live and archived webcast of the fireside chat will be available on “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.

About Pulmonx Corporation
Pulmonx Corporation (Nasdaq: LUNG) is a global

Pulmonx to Report Second Quarter 2026 Financial Results on July 29, 2026

Wed, 15 Jul 2026 16:05:00 -0400

REDWOOD CITY, Calif., July 15, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the second quarter of 2026 after the close of trading on Wednesday, July 29, 2026. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET.

A live and archived webcast of the event will be available on the “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.

About Pulmonx Corporation
Pulmonx

Pulmonx to Report Second Quarter 2026 Financial Results on July 29, 2026

Wed, 15 Jul 2026 16:05:00 -0400

A live and archived webcast of the event will be available on the “Investors” section of the Pulmonx website at https://investors.pulmonx.com/.

About Pulmonx Corporation
Pulmonx